Molecular analysis of mechanisms regulating drug sensitivity and the development of new chemotherapy strategies for genitourinary carcinomas

Seiji Naito, Hirofumi Koga, Akira Yokomizo, Naotaka Sakamoto, Shuji Kotoh, Michitaka Nakashima, Akira Kiue, Michihiko Kuwano

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The emergence of drug-resistant tumors during treatment remains one of the major obstacles in cancer chemotherapy. Overexpression of P-glycoprotein encoded by the multidrug resistance 1 (MDR1) gene or multidrug resistance-associated protein (MRP) (or both) and decreased expression of DNA topoisomerase II are responsible for expression of the multidrug resistance (MDR) phenotype. The expression of P-glycoprotein is also often observed in untreated cancers showing spontaneous MDR, such as renal cell carcinoma. Regarding cisplatin resistance, decreased cisplatin accumulation, an increase in cisplatin detoxification by glutathione-related enzymes or metallothionein (or both), and increased repair of DNA damage are all considered to play an important role. The combination of reversal agents targeting such drug resistance markers may be a way to improve the outcome of chemotherapy. Regarding the presently available reversal agents, however, clinically relevant chemosensitizing doses cannot be given to humans without inducing significant toxicity. The development of new agents that reverse drug resistance without causing significant toxicity and their clinical application based on the mechanisms regulating drug sensitivity may therefore be a potentially effective new treatment strategy for genitourinary carcinomas.

Original languageEnglish
Pages (from-to)1183-1186
Number of pages4
JournalWorld journal of surgery
Volume24
Issue number10
DOIs
Publication statusPublished - Nov 9 2000

Fingerprint

Cisplatin
Multiple Drug Resistance
P-Glycoprotein
Carcinoma
Drug Resistance
Drug Therapy
Pharmaceutical Preparations
MDR Genes
Multidrug Resistance-Associated Proteins
Neoplasms
Type II DNA Topoisomerase
Metallothionein
Renal Cell Carcinoma
DNA Damage
Glutathione
Phenotype
Enzymes
Therapeutics

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Molecular analysis of mechanisms regulating drug sensitivity and the development of new chemotherapy strategies for genitourinary carcinomas. / Naito, Seiji; Koga, Hirofumi; Yokomizo, Akira; Sakamoto, Naotaka; Kotoh, Shuji; Nakashima, Michitaka; Kiue, Akira; Kuwano, Michihiko.

In: World journal of surgery, Vol. 24, No. 10, 09.11.2000, p. 1183-1186.

Research output: Contribution to journalArticle

Naito, Seiji ; Koga, Hirofumi ; Yokomizo, Akira ; Sakamoto, Naotaka ; Kotoh, Shuji ; Nakashima, Michitaka ; Kiue, Akira ; Kuwano, Michihiko. / Molecular analysis of mechanisms regulating drug sensitivity and the development of new chemotherapy strategies for genitourinary carcinomas. In: World journal of surgery. 2000 ; Vol. 24, No. 10. pp. 1183-1186.
@article{b4ed42e7903042a9b7d88c38b2d8f33c,
title = "Molecular analysis of mechanisms regulating drug sensitivity and the development of new chemotherapy strategies for genitourinary carcinomas",
abstract = "The emergence of drug-resistant tumors during treatment remains one of the major obstacles in cancer chemotherapy. Overexpression of P-glycoprotein encoded by the multidrug resistance 1 (MDR1) gene or multidrug resistance-associated protein (MRP) (or both) and decreased expression of DNA topoisomerase II are responsible for expression of the multidrug resistance (MDR) phenotype. The expression of P-glycoprotein is also often observed in untreated cancers showing spontaneous MDR, such as renal cell carcinoma. Regarding cisplatin resistance, decreased cisplatin accumulation, an increase in cisplatin detoxification by glutathione-related enzymes or metallothionein (or both), and increased repair of DNA damage are all considered to play an important role. The combination of reversal agents targeting such drug resistance markers may be a way to improve the outcome of chemotherapy. Regarding the presently available reversal agents, however, clinically relevant chemosensitizing doses cannot be given to humans without inducing significant toxicity. The development of new agents that reverse drug resistance without causing significant toxicity and their clinical application based on the mechanisms regulating drug sensitivity may therefore be a potentially effective new treatment strategy for genitourinary carcinomas.",
author = "Seiji Naito and Hirofumi Koga and Akira Yokomizo and Naotaka Sakamoto and Shuji Kotoh and Michitaka Nakashima and Akira Kiue and Michihiko Kuwano",
year = "2000",
month = "11",
day = "9",
doi = "10.1007/s002680010200",
language = "English",
volume = "24",
pages = "1183--1186",
journal = "World Journal of Surgery",
issn = "0364-2313",
publisher = "Springer New York",
number = "10",

}

TY - JOUR

T1 - Molecular analysis of mechanisms regulating drug sensitivity and the development of new chemotherapy strategies for genitourinary carcinomas

AU - Naito, Seiji

AU - Koga, Hirofumi

AU - Yokomizo, Akira

AU - Sakamoto, Naotaka

AU - Kotoh, Shuji

AU - Nakashima, Michitaka

AU - Kiue, Akira

AU - Kuwano, Michihiko

PY - 2000/11/9

Y1 - 2000/11/9

N2 - The emergence of drug-resistant tumors during treatment remains one of the major obstacles in cancer chemotherapy. Overexpression of P-glycoprotein encoded by the multidrug resistance 1 (MDR1) gene or multidrug resistance-associated protein (MRP) (or both) and decreased expression of DNA topoisomerase II are responsible for expression of the multidrug resistance (MDR) phenotype. The expression of P-glycoprotein is also often observed in untreated cancers showing spontaneous MDR, such as renal cell carcinoma. Regarding cisplatin resistance, decreased cisplatin accumulation, an increase in cisplatin detoxification by glutathione-related enzymes or metallothionein (or both), and increased repair of DNA damage are all considered to play an important role. The combination of reversal agents targeting such drug resistance markers may be a way to improve the outcome of chemotherapy. Regarding the presently available reversal agents, however, clinically relevant chemosensitizing doses cannot be given to humans without inducing significant toxicity. The development of new agents that reverse drug resistance without causing significant toxicity and their clinical application based on the mechanisms regulating drug sensitivity may therefore be a potentially effective new treatment strategy for genitourinary carcinomas.

AB - The emergence of drug-resistant tumors during treatment remains one of the major obstacles in cancer chemotherapy. Overexpression of P-glycoprotein encoded by the multidrug resistance 1 (MDR1) gene or multidrug resistance-associated protein (MRP) (or both) and decreased expression of DNA topoisomerase II are responsible for expression of the multidrug resistance (MDR) phenotype. The expression of P-glycoprotein is also often observed in untreated cancers showing spontaneous MDR, such as renal cell carcinoma. Regarding cisplatin resistance, decreased cisplatin accumulation, an increase in cisplatin detoxification by glutathione-related enzymes or metallothionein (or both), and increased repair of DNA damage are all considered to play an important role. The combination of reversal agents targeting such drug resistance markers may be a way to improve the outcome of chemotherapy. Regarding the presently available reversal agents, however, clinically relevant chemosensitizing doses cannot be given to humans without inducing significant toxicity. The development of new agents that reverse drug resistance without causing significant toxicity and their clinical application based on the mechanisms regulating drug sensitivity may therefore be a potentially effective new treatment strategy for genitourinary carcinomas.

UR - http://www.scopus.com/inward/record.url?scp=0033736398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033736398&partnerID=8YFLogxK

U2 - 10.1007/s002680010200

DO - 10.1007/s002680010200

M3 - Article

C2 - 11071457

AN - SCOPUS:0033736398

VL - 24

SP - 1183

EP - 1186

JO - World Journal of Surgery

JF - World Journal of Surgery

SN - 0364-2313

IS - 10

ER -